Regeneron Antibody Cocktail May Reduce COVID-19 Hospitalization by 70%

Results from a phase 3 clinical trial show that Regeneron's antibody cocktail has the ability to cut the risk of hospitalization and death by 70 percent.

No comments:

Post a Comment